UK markets closed
  • FTSE 100

    7,500.89
    +34.98 (+0.47%)
     
  • FTSE 250

    20,338.96
    +93.53 (+0.46%)
     
  • AIM

    933.20
    +4.84 (+0.52%)
     
  • GBP/EUR

    1.1820
    +0.0002 (+0.02%)
     
  • GBP/USD

    1.2139
    -0.0064 (-0.52%)
     
  • BTC-GBP

    20,076.72
    +402.46 (+2.05%)
     
  • CMC Crypto 200

    574.64
    +3.36 (+0.59%)
     
  • S&P 500

    4,280.15
    +72.88 (+1.73%)
     
  • DOW

    33,761.05
    +424.38 (+1.27%)
     
  • CRUDE OIL

    91.88
    -2.46 (-2.61%)
     
  • GOLD FUTURES

    1,818.90
    +11.70 (+0.65%)
     
  • NIKKEI 225

    28,546.98
    +727.65 (+2.62%)
     
  • HANG SENG

    20,175.62
    +93.19 (+0.46%)
     
  • DAX

    13,795.85
    +101.34 (+0.74%)
     
  • CAC 40

    6,553.86
    +9.19 (+0.14%)
     

Global T-Cell Immunotherapy Market Report to 2027 - Featuring Atara Biotherapeutics, Autolus and bluebird bio Among Others

·4-min read
Company Logo
Company Logo

Global T-Cell Immunotherapy Market

Global T-Cell Immunotherapy Market
Global T-Cell Immunotherapy Market

Dublin, July 21, 2022 (GLOBE NEWSWIRE) -- The "T-Cell Immunotherapy Market Intelligence Report - Global Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.

The Global T-Cell Immunotherapy Market is projected to reach USD 9,684.58 million by 2027 from USD 4,712.10 million in 2021, at a CAGR 12.75% during the forecast period.

Market Statistics:

The report provides market sizing and forecast across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2019 and 2020 are considered historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered the forecast period.

  • The Americas T-Cell Immunotherapy Market size was estimated at USD 1,633.21 million in 2021 and expected to reach USD 1,848.63 million in 2022, at a CAGR 12.92% to reach USD 3,386.23 million by 2027.

  • The Asia-Pacific T-Cell Immunotherapy Market size was estimated at USD 1,076.95 million in 2021 and expected to reach USD 1,237.07 million in 2022, at a CAGR 13.46% to reach USD 2,297.78 million by 2027.

  • The Europe, Middle East & Africa T-Cell Immunotherapy Market size was estimated at USD 2,001.93 million in 2021 and expected to reach USD 2,224.18 million in 2022, at a CAGR 12.23% to reach USD 4,000.57 million by 2027.

Market Segmentation & Coverage:

The report on t-cell immunotherapy identifies key attributes about the customer to define the potential market and identify different needs across the industry. Understanding the potential customer group's economies and geographies can help gain business acumen for better strategic decision-making.

The market coverage across different industry verticals reveals the hidden truth about the players' strategies in different verticals and helps the organization decide target audience. This report gives you the composite view of sub-markets coupled with comprehensive industry coverage and provides you with the right way of accounting factors such as norms & regulations, culture, to make right coverage strategy for your market plan.

Key Topics Covered:

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Market Overview

4. Americas T-Cell Immunotherapy Market
4.1. Introduction
4.2. Argentina
4.3. Brazil
4.4. Canada
4.5. Mexico
4.6. United States

5. Asia-Pacific T-Cell Immunotherapy Market
5.1. Introduction
5.2. Australia
5.3. China
5.4. India
5.5. Indonesia
5.6. Japan
5.7. Malaysia
5.8. Philippines
5.9. Singapore
5.10. South Korea
5.11. Taiwan
5.12. Thailand

6. Europe, Middle East & Africa T-Cell Immunotherapy Market
6.1. Introduction
6.2. France
6.3. Germany
6.4. Italy
6.5. Netherlands
6.6. Qatar
6.7. Russia
6.8. Saudi Arabia
6.9. South Africa
6.10. Spain
6.11. United Arab Emirates
6.12. United Kingdom

7. Company Usability Profiles
7.1. Adaptimmune Therapeutics PLC
7.2. Apac Biotech
7.3. Atara Biotherapeutics, Inc.
7.4. Autolus Limited
7.5. bluebird bio, Inc.
7.6. Bristol-Myers Squibb Company
7.7. CARsgen Therapeutics, Ltd
7.8. Cellectis SA
7.9. Chimera Bioengineering
7.10. Dendreon Pharmaceuticals LLC
7.11. Eureka Therapeutics, Inc.
7.12. Gilead Sciences, Inc.
7.13. Green Cross Corporation
7.14. Innovative Cellular Therapeutics
7.15. Iovance Biotherapeutics, Inc.
7.16. JW CreaGene Co., Ltd.
7.17. LAVA Therapeutics BV
7.18. Lyell Immunopharma
7.19. Neogene Therapeutics
7.20. NeoTX Therapeutics
7.21. Novartis AG
7.22. Oxford Vacmedix
7.23. Poseida Therapeutics
7.24. TScan Therapeutics, Inc.
7.25. Xenetic Biosciences
7.26. ZIOPHARM Oncology

For more information about this report visit https://www.researchandmarkets.com/r/vd2sok

Attachment

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting